1-methylpropyl-2-imidazolyl disulfide profile

1-methylpropyl-2-imidazolyl disulfide: a thioredoxin inhibitor with antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	219104
CHEMBL ID	406050
CHEBI ID	94291
SCHEMBL ID	775481
MeSH ID	M0369161

Synonym
iv 2 compound
141400-58-0
iv-2 compound
1h-imidazole, 2-((1-methylpropyl)dithio)-
unii-8pq9cz8btj
2-((1-methylpropyl)dithio)-1h-imidazole
1-methylpropyl-2-imidazolyl disulfide
8pq9cz8btj ,
px-12 compound
px 12
px-12
CHEMBL406050 ,
2-(sec-butyldisulfanyl)-1h-imidazole
1-methylpropyl 2-imidazolyl disulfide
2-(butan-2-yldisulfanyl)-1h-imidazole
2-[(1-methylpropyl)dithio]-1h-imidazole
NCGC00346876-01
S7947
BRD-A56592690-001-01-9
bdbm50426071
DB05448
HY-13734
AKOS022175532
SCHEMBL775481
c7h12n2s2
iv-2
1h-imidazole, 2-[(1-methylpropyl)dithio]-
AC-32876
mfcd18086851
px12
CHEBI:94291
px 12, >=98% (hplc), powder
J-007491
s-butyl (2-imidazolyl) disulfide
DTXSID50875689
2-(sec-butyldisulfanyl)-1h-imidazole.
EX-A2436
Q27095678
BCP08978
HMS3871E03
HMS3747E17
CCG-266487
iv-2;px12
AS-55822
BP177052

Class	Description
imidazoles	A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Fumarate hydratase	Homo sapiens (human)	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
EWS/FLI fusion protein	Homo sapiens (human)	Potency	22.7930	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
polyprotein	Zika virus	Potency	37.2212	0.0030	8.7949	48.0869	AID1347053
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Spike glycoprotein	Betacoronavirus England 1	IC50 (µMol)	21.0000	0.0300	2.7283	9.5100	AID1804127
Replicase polyprotein 1ab	Betacoronavirus England 1	IC50 (µMol)	16.5333	0.0040	3.4388	9.5100	AID1640022; AID1804127
Transmembrane protease serine 2	Homo sapiens (human)	IC50 (µMol)	21.0000	0.0180	2.6198	9.5100	AID1804127
Procathepsin L	Homo sapiens (human)	IC50 (µMol)	21.0000	0.0002	1.6661	9.5100	AID1804127
Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	21.0000	0.0300	2.2971	9.5100	AID1804127
Replicase polyprotein 1ab	Human coronavirus 229E	IC50 (µMol)	21.0000	0.0300	2.1441	9.5100	AID1804127
Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	21.1300	0.0040	2.9266	9.9600	AID1804127; AID1805801
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	IC50 (µMol)	18.2414	0.0002	2.4585	9.9600	AID1640021; AID1803933; AID1804127; AID1805801; AID1845234; AID1845236
Thioredoxin	Homo sapiens (human)	IC50 (µMol)	2.1100	2.1100	2.1100	2.1100	AID722340
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	IC50 (µMol)	21.0000	0.0300	2.7731	9.5100	AID1804127
Angiotensin-converting enzyme 2	Homo sapiens (human)	IC50 (µMol)	21.0000	0.0004	2.2079	10.0000	AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
viral translation	Transmembrane protease serine 2	Homo sapiens (human)
proteolysis	Transmembrane protease serine 2	Homo sapiens (human)
protein autoprocessing	Transmembrane protease serine 2	Homo sapiens (human)
positive regulation of viral entry into host cell	Transmembrane protease serine 2	Homo sapiens (human)
adaptive immune response	Procathepsin L	Homo sapiens (human)
proteolysis	Procathepsin L	Homo sapiens (human)
protein autoprocessing	Procathepsin L	Homo sapiens (human)
fusion of virus membrane with host plasma membrane	Procathepsin L	Homo sapiens (human)
receptor-mediated endocytosis of virus by host cell	Procathepsin L	Homo sapiens (human)
antigen processing and presentation	Procathepsin L	Homo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class II	Procathepsin L	Homo sapiens (human)
collagen catabolic process	Procathepsin L	Homo sapiens (human)
zymogen activation	Procathepsin L	Homo sapiens (human)
enkephalin processing	Procathepsin L	Homo sapiens (human)
fusion of virus membrane with host endosome membrane	Procathepsin L	Homo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitment	Procathepsin L	Homo sapiens (human)
symbiont entry into host cell	Procathepsin L	Homo sapiens (human)
antigen processing and presentation of peptide antigen	Procathepsin L	Homo sapiens (human)
proteolysis involved in protein catabolic process	Procathepsin L	Homo sapiens (human)
elastin catabolic process	Procathepsin L	Homo sapiens (human)
macrophage apoptotic process	Procathepsin L	Homo sapiens (human)
cellular response to thyroid hormone stimulus	Procathepsin L	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Procathepsin L	Homo sapiens (human)
positive regulation of peptidase activity	Procathepsin L	Homo sapiens (human)
immune response	Procathepsin L	Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
negative regulation of transcription by RNA polymerase II	Thioredoxin	Homo sapiens (human)
response to radiation	Thioredoxin	Homo sapiens (human)
activation of protein kinase B activity	Thioredoxin	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Thioredoxin	Homo sapiens (human)
positive regulation of DNA binding	Thioredoxin	Homo sapiens (human)
cell redox homeostasis	Thioredoxin	Homo sapiens (human)
negative regulation of protein export from nucleus	Thioredoxin	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Thioredoxin	Homo sapiens (human)
cellular detoxification of hydrogen peroxide	Thioredoxin	Homo sapiens (human)
response to nitric oxide	Thioredoxin	Homo sapiens (human)
positive regulation of peptidyl-cysteine S-nitrosylation	Thioredoxin	Homo sapiens (human)
negative regulation of signaling receptor activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
symbiont entry into host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of cytokine production	Angiotensin-converting enzyme 2	Homo sapiens (human)
angiotensin maturation	Angiotensin-converting enzyme 2	Homo sapiens (human)
angiotensin-mediated drinking behavior	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensin	Angiotensin-converting enzyme 2	Homo sapiens (human)
tryptophan transport	Angiotensin-converting enzyme 2	Homo sapiens (human)
viral life cycle	Angiotensin-converting enzyme 2	Homo sapiens (human)
receptor-mediated endocytosis of virus by host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of vasoconstriction	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of transmembrane transporter activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of cell population proliferation	Angiotensin-converting enzyme 2	Homo sapiens (human)
symbiont entry into host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
receptor-mediated virion attachment to host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
negative regulation of smooth muscle cell proliferation	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of inflammatory response	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of amino acid transport	Angiotensin-converting enzyme 2	Homo sapiens (human)
maternal process involved in female pregnancy	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane fusion	Angiotensin-converting enzyme 2	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Angiotensin-converting enzyme 2	Homo sapiens (human)
blood vessel diameter maintenance	Angiotensin-converting enzyme 2	Homo sapiens (human)
entry receptor-mediated virion attachment to host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of gap junction assembly	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of cardiac conduction	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of L-proline import across plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
serine-type endopeptidase activity	Transmembrane protease serine 2	Homo sapiens (human)
protein binding	Transmembrane protease serine 2	Homo sapiens (human)
serine-type peptidase activity	Transmembrane protease serine 2	Homo sapiens (human)
fibronectin binding	Procathepsin L	Homo sapiens (human)
cysteine-type endopeptidase activity	Procathepsin L	Homo sapiens (human)
protein binding	Procathepsin L	Homo sapiens (human)
collagen binding	Procathepsin L	Homo sapiens (human)
cysteine-type peptidase activity	Procathepsin L	Homo sapiens (human)
histone binding	Procathepsin L	Homo sapiens (human)
proteoglycan binding	Procathepsin L	Homo sapiens (human)
serpin family protein binding	Procathepsin L	Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic process	Procathepsin L	Homo sapiens (human)
RNA-dependent RNA polymerase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoesters	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
protein guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA binding	Thioredoxin	Homo sapiens (human)
thioredoxin-disulfide reductase (NADPH) activity	Thioredoxin	Homo sapiens (human)
protein binding	Thioredoxin	Homo sapiens (human)
protein-disulfide reductase activity	Thioredoxin	Homo sapiens (human)
protein homodimerization activity	Thioredoxin	Homo sapiens (human)
protein-disulfide reductase (NAD(P)H) activity	Thioredoxin	Homo sapiens (human)
virus receptor activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
endopeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
carboxypeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
metallocarboxypeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
protein binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
metallopeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
peptidyl-dipeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
zinc ion binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
identical protein binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Transmembrane protease serine 2	Homo sapiens (human)
nucleoplasm	Transmembrane protease serine 2	Homo sapiens (human)
plasma membrane	Transmembrane protease serine 2	Homo sapiens (human)
extracellular exosome	Transmembrane protease serine 2	Homo sapiens (human)
extracellular region	Procathepsin L	Homo sapiens (human)
extracellular space	Procathepsin L	Homo sapiens (human)
nucleus	Procathepsin L	Homo sapiens (human)
lysosome	Procathepsin L	Homo sapiens (human)
multivesicular body	Procathepsin L	Homo sapiens (human)
Golgi apparatus	Procathepsin L	Homo sapiens (human)
plasma membrane	Procathepsin L	Homo sapiens (human)
apical plasma membrane	Procathepsin L	Homo sapiens (human)
endolysosome lumen	Procathepsin L	Homo sapiens (human)
chromaffin granule	Procathepsin L	Homo sapiens (human)
lysosomal lumen	Procathepsin L	Homo sapiens (human)
intracellular membrane-bounded organelle	Procathepsin L	Homo sapiens (human)
collagen-containing extracellular matrix	Procathepsin L	Homo sapiens (human)
extracellular exosome	Procathepsin L	Homo sapiens (human)
endocytic vesicle lumen	Procathepsin L	Homo sapiens (human)
extracellular space	Procathepsin L	Homo sapiens (human)
lysosome	Procathepsin L	Homo sapiens (human)
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
extracellular region	Thioredoxin	Homo sapiens (human)
nucleus	Thioredoxin	Homo sapiens (human)
nucleoplasm	Thioredoxin	Homo sapiens (human)
cytoplasm	Thioredoxin	Homo sapiens (human)
cytosol	Thioredoxin	Homo sapiens (human)
extracellular exosome	Thioredoxin	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular region	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme 2	Homo sapiens (human)
endoplasmic reticulum lumen	Angiotensin-converting enzyme 2	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
cilium	Angiotensin-converting enzyme 2	Homo sapiens (human)
cell surface	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
apical plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
endocytic vesicle membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
brush border membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane raft	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular exosome	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (89)

Assay ID	Title	Year	Journal	Article
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1805801	Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Perspectives on SARS-CoV-2 Main Protease Inhibitors.
AID1803933	high-throughput activity assay from Article 10.1038/s41586-020-2223-y: \\Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors \\	2020	Nature, 06, Volume: 582, Issue:7811	Structure of M
AID1804127	No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\	2021	Medicinal research reviews, 01, Volume: 41, Issue:1	The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID653519	Cytotoxicity against mouse EMT6 cells after 72 hrs by crystal violet staining	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID722340	Inhibition of human recombinant thioredoxin-mediated TG2 activation expressed in T84 cells assessed as blockade of 5-biotinamidopentylamine incorporation after 3 hrs by fluorescence microscopic analysis	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Selective inhibition of extracellular thioredoxin by asymmetric disulfides.
AID653521	Inhibition of human recombinant Trx1/TrxR assessed as reduction in number of free thiols from reduced insulin after 30 mins by insulin reduction assay	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID653524	Cytotoxicity against mouse MEF cells	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID331396	Antiproliferative activity against human HT29 cells	2008	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12	Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation.
AID331397	Antiproliferative activity against human M21 cells	2008	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12	Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation.
AID1692494	Inhibition of SARS-CoV2 3C-like protease expressed in Escherichia coli BL21 (DE3) cells using Mca-AVLQSGFR-K(Dnp)K as substrate by fluorescence method	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	COVID-19: Drug Targets and Potential Treatments.
AID653512	Cytotoxicity against human Ramos cells after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID653539	Toxicity in mouse EMT6 cells allografted BALB/c mouse assessed as mortality at 14 mg/kg, ip qd for 7 days measured on day 5	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID653520	Cytotoxicity against mouse PancO2 cells after 72 hrs by crystal violet staining	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID342593	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 2 times GI50 after 24 hrs by flow cytometry	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
AID653511	Cytotoxicity against human Raji cells after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID653510	Cytotoxicity against human K562 cells after 72 hrs by MTT assay	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID342594	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 2 times GI50 after 24 hrs by flow cytometry	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
AID653533	Induction of Trx protein expression in human Raji cells at 10 to 20 uM after 4 to 8 hrs by Western blot analysis	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID342591	Antiproliferative activity against human HT29 cells after 48 hrs by sulforhodamine B method	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
AID653522	Cytotoxicity against human T24 cells after 72 hrs by crystal violet staining	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID653525	Cytotoxicity against human PBMC cells after 72 hrs by XTT assay	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID342601	Stimulation of nuclear translocation of thioredoxin-1 from cytosol in human M21 cells at 25 nM after 16 hrs by immunocytofluorescence	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
AID722343	Inhibition of wild type human thioredoxin	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Selective inhibition of extracellular thioredoxin by asymmetric disulfides.
AID653532	Induction of Trx mRNA expression in human Raji cells at 5 to 10 uM after 4 to 24 hrs by RT-PCR analysis	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID653523	Cytotoxicity against mouse bone marrow cells after 72 hrs by XTT assay	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID331402	Cell cycle arrest in human MCF7 cells assessed as increase in G0/G1 phase accumulation at 25 uM after 16 hrs by FACS analysis	2008	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12	Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation.
AID331408	Cell cycle arrest in human MCF7 cells assessed as increase in G2/M phase accumulation at 25 uM after 16 hrs by FACS analysis	2008	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12	Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation.
AID331405	Cell cycle arrest in human MCF7 cells assessed as increase in S phase accumulation at 25 uM after 16 hrs by FACS analysis	2008	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12	Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation.
AID342597	Induction of beta2-tubulin alkylation in human M21 cells at 2 times GI50 by Western blot analysis	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
AID1845234	Inhibition of SARS-CoV-2 MPro expressed in Escherichia coli BL21 (DE3) using Mca-AVLQ SGFR-K(Dnp)K as substrate by EnVision multimode plate reader analysis	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID331398	Antiproliferative activity against human MCF7 cells	2008	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12	Cycloalkyl-substituted aryl chloroethylureas inhibiting cell cycle progression in G0/G1 phase and thioredoxin-1 nuclear translocation.
AID342589	Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B method	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
AID653513	Cytotoxicity against mouse B78 cells after 72 hrs by crystal violet staining	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID722342	Inhibition of human thioredoxin relative to DTT	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Selective inhibition of extracellular thioredoxin by asymmetric disulfides.
AID342590	Antiproliferative activity against human M21 cells after 48 hrs by sulforhodamine B method	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
AID653538	Toxicity in mouse EMT6 cells allografted BALB/c mouse assessed as change in body weight at 14 mg/kg, ip qd for 7 days measured on day 5	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID342592	Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 2 times GI50 after 24 hrs by flow cytometry	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
AID653514	Cytotoxicity against wild type mouse CT26 cells after 72 hrs by crystal violet staining	2012	Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1	Studies toward novel peptidomimetic inhibitors of thioredoxin-thioredoxin reductase system.
AID1845236	Inhibition of SARS-CoV-2 MPro	2021	Bioorganic & medicinal chemistry, 01-01, Volume: 29	Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (22.95)	29.6817
2010's	31 (50.82)	24.3611
2020's	16 (26.23)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	5 (8.20%)	5.53%
Reviews	7 (11.48%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	49 (80.33%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
Enhancement of metabolic oxidative stress-induced cytotoxicity by the thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide is mediated through the ASK1-SEK1-JNK1 pathway. Molecular pharmacology, Volume: 62, Issue: 6	2002
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, Apr-01, Volume: 13, Issue: 7	2007
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Article	Year
A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, Apr-01, Volume: 13, Issue: 7	2007
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

1-methylpropyl-2-imidazolyl disulfide

Description

Cross-References

Synonyms (45)

Drug Classes (1)

Protein Targets (14)

Potency Measurements

Inhibition Measurements

Biological Processes (59)

Molecular Functions (35)

Ceullar Components (27)

Bioassays (89)

Research

Studies (61)

Study Types

Research Highlights

Safety/Toxicity (1)

Pharmacokinetics (1)

Bioavailability (1)

Dosage (1)

Condition	Relationship Strength	Studies	Trials
2019 Novel Coronavirus Disease	low	2	0
2019 Novel Coronavirus Infection	low	2	0
2019-nCoV Disease	low	2	0
2019-nCoV Infection	low	2	0
Acute Lymphoid Leukemia	low	2	0
Acute Myelogenous Leukemia	low	1	0
Acute Myeloid Leukemia	low	1	0
Acute Myeloid Leukemia with Maturation	low	1	0
Acute Myeloid Leukemia without Maturation	low	1	0
ALL, Childhood	low	2	0
Allodynia	low	1	0
Allodynia, Mechanical	low	1	0
Allodynia, Tactile	low	1	0
Allodynia, Thermal	low	1	0
Alloxan Diabetes	low	1	0
Androgen-Independent Prostatic Cancer	low	1	0
Androgen-Independent Prostatic Neoplasms	low	1	0
Androgen-Insensitive Prostatic Cancer	low	1	0
Androgen-Insensitive Prostatic Neoplasms	low	1	0
Androgen-Resistant Prostatic Cancer	low	1	0
Androgen-Resistant Prostatic Neoplasms	low	1	0
ANLL	low	1	0
Anoxemia	low	1	0
Anoxia	low	1	0
Astrocytoma, Grade IV	low	1	0
ATLL	low	1	0
Benign Neoplasms	medium	7	3
Blood Clot	low	1	0
Botulism	low	1	0
Botulism, Infantile	low	1	0
Botulism, Toxico-Infectious	low	1	0
Brain Ischemia	low	1	0
Breast Cancer	low	2	0
Breast Carcinoma	low	2	0
Breast Neoplasms	low	2	0
Breast Tumors	low	2	0
Cancer	medium	7	3
Cancer of Breast	low	2	0
Cancer of Colon	low	2	0
Cancer of Gastrointestinal Tract	medium	1	1
Cancer of Kidney	low	1	0
Cancer of Liver	low	1	0
Cancer of Lung	low	1	0
Cancer of Mouth	low	1	0
Cancer of Pancreas	medium	1	1
Cancer of Prostate	low	1	0
Cancer of Stomach	low	1	0
Cancer of the Breast	low	2	0
Cancer of the Colon	low	2	0
Cancer of the Gastrointestinal Tract	medium	1	1
Cancer of the Kidney	low	1	0
Cancer of the Liver	low	1	0
Cancer of the Lung	low	1	0
Cancer of the Mouth	low	1	0
Cancer of the Pancreas	medium	1	1
Cancer of the Prostate	low	1	0
Cancer of the Stomach	low	1	0
Cancer, Hepatocellular	low	1	0
Carcinogenesis	low	1	0
Carcinoma, Epidermoid	low	1	0
Carcinoma, Hepatocellular	low	1	0
Carcinoma, Planocellular	low	1	0
Carcinoma, Squamous	low	1	0
Carcinoma, Squamous Cell	low	1	0
Castration-Resistant Prostatic Cancer	low	1	0
Castration-Resistant Prostatic Neoplasms	low	1	0
Celiac Disease	low	1	0
Celiac Sprue	low	1	0
Cell Transformation, Neoplastic	low	1	0
Cerebral Infarction, Middle Cerebral Artery	low	1	0
Cerebral Ischemia	low	1	0
Clostridium botulinum Infection	low	1	0
Clostridium tetani Infection	low	1	0
Colon Cancer	low	2	0
Colon Neoplasms	low	2	0
Colonic Cancer	low	2	0
Colonic Neoplasms	low	2	0
Colorectal Cancer	low	1	0
Colorectal Carcinoma	low	1	0
Colorectal Neoplasms	low	1	0
Colorectal Tumors	low	1	0
Complex Regional Pain Syndrome	low	1	0
Complex Regional Pain Syndromes	low	1	0
Condition, Preneoplastic	low	1	0
Conditions, Preneoplastic	low	1	0
Congenital Zika Syndrome	low	1	0
Congenital Zika Virus Infection	low	1	0
Coronavirus Disease 2019	low	2	0
Coronavirus Disease-19	low	2	0
Coronavirus Infections	low	1	0
COVID-19	low	2	0
COVID-19 Pandemic	low	2	0
COVID-19 Pandemics	low	2	0
COVID-19 Virus Disease	low	2	0
COVID-19 Virus Infection	low	2	0
COVID19	low	2	0
CRPS (Complex Regional Pain Syndromes)	low	1	0
Deficiency, Oxygen	low	1	0
Diabetes Mellitus, Experimental	low	1	0
Diabetic Retinopathy	low	1	0
Disease Exacerbation	medium	4	1
Disease Models, Animal	low	3	0
Disease Progression	medium	4	1
Embolic Infarction, Middle Cerebral Artery	low	1	0
Embolus, Middle Cerebral Artery	low	1	0
Encephalopathy, Ischemic	low	1	0
ER-Negative PR-Negative HER2-Negative Breast Cancer	low	1	0
ER-Negative PR-Negative HER2-Negative Breast Neoplasms	low	1	0
Experimental Diabetes Mellitus	low	1	0
Experimental Neoplasms	low	1	0
Fever, Zika	low	1	0
Foodborne Botulism	low	1	0
Fractures, Ununited	low	1	0
Gastric Cancer	low	1	0
Gastric Cancer, Familial Diffuse	low	1	0
Gastric Neoplasms	low	1	0
Gastrointestinal Cancer	medium	1	1
Gastrointestinal Neoplasms	medium	1	1
Giant Cell Glioblastoma	low	1	0
Glial Cell Tumors	low	1	0
Glioblastoma	low	1	0
Glioblastoma Multiforme	low	1	0
Glioma	low	1	0
Gluten Enteropathy	low	1	0
Gluten-Sensitive Enteropathy	low	1	0
Hepatic Cancer	low	1	0
Hepatic Neoplasms	low	1	0
Hepatocellular Cancer	low	1	0
Hepatocellular Carcinoma	low	1	0
Hepatoma	low	1	0
HIV Coinfection	low	1	0
HIV Infections	low	1	0
Hormone Refractory Prostatic Cancer	low	1	0
Hormone Refractory Prostatic Neoplasms	low	1	0
HTLV I Associated T Cell Leukemia Lymphoma	low	1	0
HTLV-Associated Leukemia-Lymphoma	low	1	0
HTLV-I-Associated T-Cell Leukemia-Lymphoma	low	1	0
HTLV-III Infections	low	1	0
HTLV-III-LAV Infections	low	1	0
Human Mammary Carcinoma	low	2	0
Human T Lymphotropic Virus Associated Leukemia Lymphoma	low	1	0
Human T Lymphotropic Virus-Associated Leukemia-Lymphoma	low	1	0
Human T-Cell Leukemia-Lymphoma	low	1	0
Hyperalgesia	low	1	0
Hyperalgesia, Mechanical	low	1	0
Hyperalgesia, Primary	low	1	0
Hyperalgesia, Secondary	low	1	0
Hyperalgesia, Tactile	low	1	0
Hyperalgesia, Thermal	low	1	0
Hyperalgesic Sensations	low	1	0
Hyperalgia	low	1	0
Hyperalgia, Mechanical	low	1	0
Hyperalgia, Primary	low	1	0
Hyperalgia, Secondary	low	1	0
Hyperglycemia	low	1	0
Hyperglycemia, Postprandial	low	1	0
Hypoxemia	low	1	0
Hypoxia	low	1	0
Infant Botulism	low	1	0
Infarction, Middle Cerebral Artery	low	1	0
Infections, Coronavirus	low	1	0
Inflammation	low	1	0
Innate Inflammatory Response	low	1	0
Invasiveness, Neoplasm	low	2	0
Ischemia, Cerebral	low	1	0
Ischemic Encephalopathy	low	1	0
Kahler Disease	low	2	0
Kidney Cancer	low	1	0
Kidney Neoplasms	low	1	0
Left Middle Cerebral Artery Infarction	low	1	0
Leukemia Lymphoma, Adult T Cell	low	1	0
Leukemia Lymphoma, T Cell, Acute, HTLV I Associated	low	1	0
Leukemia-Lymphoma, Adult T-Cell	low	1	0
Leukemia-Lymphoma, T-Cell, Acute, HTLV-I-Associated	low	1	0
Leukemia, Acute Lymphoblastic	low	2	0
Leukemia, Acute Myelogenous	low	1	0
Leukemia, Acute Myeloid	low	1	0
Leukemia, Adult T-Cell	low	1	0
Leukemia, Lymphoblastic	low	2	0
Leukemia, Lymphoblastic, Acute	low	2	0
Leukemia, Lymphoblastic, Acute, L1	low	2	0
Leukemia, Lymphoblastic, Acute, L2	low	2	0
Leukemia, Lymphoblastic, Acute, Philadelphia-Positive	low	2	0
Leukemia, Lymphocytic, Acute	low	2	0
Leukemia, Lymphocytic, Acute, L1	low	2	0
Leukemia, Lymphocytic, Acute, L2	low	2	0
Leukemia, Lymphoid, Acute	low	2	0
Leukemia, Myeloblastic, Acute	low	1	0
Leukemia, Myelocytic, Acute	low	1	0
Leukemia, Myelogenous, Acute	low	1	0
Leukemia, Myeloid, Acute	low	1	0
Leukemia, Myeloid, Acute, M1	low	1	0
Leukemia, Myeloid, Acute, M2	low	1	0
Leukemia, Nonlymphoblastic, Acute	low	1	0
Leukemia, Nonlymphocytic, Acute	low	1	0
Liver Cancer	low	1	0
Liver Cancer, Adult	low	1	0
Liver Cell Carcinoma	low	1	0
Liver Cell Carcinoma, Adult	low	1	0
Liver Neoplasms	low	1	0
Lung Cancer	low	1	0
Lung Neoplasms	low	1	0
Lymph Node Metastasis	low	1	0
Lymphatic Metastasis	low	1	0
Lymphoblastic Leukemia	low	2	0
Lymphoblastic Leukemia, Acute	low	2	0
Lymphoblastic Leukemia, Acute, Adult	low	2	0
Lymphoblastic Leukemia, Acute, Childhood	low	2	0
Lymphoblastic Leukemia, Acute, L1	low	2	0
Lymphoblastic Leukemia, Acute, L2	low	2	0
Lymphoblastic Lymphoma	low	2	0
Lymphocytic Leukemia, Acute	low	2	0
Lymphocytic Leukemia, L1	low	2	0
Lymphocytic Leukemia, L2	low	2	0
Lymphoma, Lymphoblastic	low	2	0
Malignancy	medium	7	3
Malignant Glioma	low	1	0
Malignant Neoplasm of Breast	low	2	0
Malignant Neoplasms	medium	7	3
Malignant Tumor of Breast	low	2	0
Mammary Cancer	low	2	0
Mammary Carcinoma, Human	low	2	0
Mammary Neoplasm, Human	low	2	0
Mammary Neoplasms, Human	low	2	0
MCA Infarct	low	1	0
MCA Infarction	low	1	0
Mechanical Allodynia	low	1	0
Mechanical Hyperalgesia	low	1	0
MERS (Middle East Respiratory Syndrome)	low	1	0
Metastase	low	2	0
Metastases, Neoplasm	low	2	0
Metastasis	low	2	0
Metastasis, Neoplasm	low	2	0
Middle Cerebral Artery Circulation Infarction	low	1	0
Middle Cerebral Artery Embolic Infarction	low	1	0
Middle Cerebral Artery Embolus	low	1	0
Middle Cerebral Artery Infarction	low	1	0
Middle Cerebral Artery Occlusion	low	1	0
Middle Cerebral Artery Stroke	low	1	0
Middle Cerebral Artery Syndrome	low	1	0
Middle Cerebral Artery Thrombosis	low	1	0
Middle Cerebral Artery Thrombotic Infarction	low	1	0
Middle East Respiratory Syndrome	low	1	0
Mixed Glioma	low	1	0
Mouth Cancer	low	1	0
Mouth Neoplasms	low	1	0
Multiple Myeloma	low	2	0
Myeloblastic Leukemia, Acute	low	1	0
Myelocytic Leukemia, Acute	low	1	0
Myelogenous Leukemia, Acute	low	1	0
Myeloid Leukemia, Acute	low	1	0
Myeloid Leukemia, Acute, M1	low	1	0
Myeloid Leukemia, Acute, M2	low	1	0
Myeloma-Multiple	low	2	0
Myeloma, Multiple	low	2	0
Myeloma, Plasma-Cell	low	2	0
Myelomatosis	low	2	0
Neoplasia	medium	7	3
Neoplasm	medium	7	3
Neoplasm Invasion	low	2	0
Neoplasm Invasiveness	low	2	0
Neoplasm Metastases	low	2	0
Neoplasm Metastasis	low	2	0
Neoplasms	medium	7	3
Neoplasms, Benign	medium	7	3
Neoplasms, Breast	low	2	0
Neoplasms, Colonic	low	2	0
Neoplasms, Colorectal	low	1	0
Neoplasms, Experimental	low	1	0
Neoplasms, Gastric	low	1	0
Neoplasms, Gastrointestinal	medium	1	1
Neoplasms, Hepatic	low	1	0
Neoplasms, Kidney	low	1	0
Neoplasms, Liver	low	1	0
Neoplasms, Lung	low	1	0
Neoplasms, Mouth	low	1	0
Neoplasms, Oral	low	1	0
Neoplasms, Pancreatic	medium	1	1
Neoplasms, Prostate	low	1	0
Neoplasms, Prostatic	low	1	0
Neoplasms, Pulmonary	low	1	0
Neoplasms, Stomach	low	1	0
Neoplastic Cell Transformation	low	1	0
Neoplastic Transformation, Cell	low	1	0
Nonlymphoblastic Leukemia, Acute	low	1	0
Nonlymphocytic Leukemia, Acute	low	1	0
Occlusion, Middle Cerebral Artery	low	1	0
Oncogenesis	low	1	0
Oral Cancer	low	1	0
Oral Neoplasms	low	1	0
Oxygen Deficiency	low	1	0
Pain Syndromes, Regional Complex	low	1	0
Palsy	low	1	0
Pancreas Cancer	medium	1	1
Pancreas Neoplasms	medium	1	1
Pancreatic Cancer	medium	1	1
Paralysis	low	1	0
Plasma Cell Myeloma	low	2	0
Plegia	low	1	0
Pneumonia, Viral	low	1	0
Postprandial Hyperglycemia	low	1	0
Precancerous Conditions	low	1	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma	low	2	0
Preneoplastic Condition	low	1	0
Preneoplastic Conditions	low	1	0
Prostate Cancer	low	1	0
Prostate Neoplasms	low	1	0
Prostatic Cancer	low	1	0
Prostatic Cancer, Androgen-Independent	low	1	0
Prostatic Cancer, Androgen-Insensitive	low	1	0
Prostatic Cancer, Androgen-Resistant	low	1	0
Prostatic Cancer, Castration-Resistant	low	1	0
Prostatic Cancer, Hormone Refractory	low	1	0
Prostatic Neoplasms	low	1	0
Prostatic Neoplasms, Androgen-Independent	low	1	0
Prostatic Neoplasms, Androgen-Insensitive	low	1	0
Prostatic Neoplasms, Androgen-Resistant	low	1	0
Prostatic Neoplasms, Castration-Resistant	low	1	0
Prostatic Neoplasms, Hormone Refractory	low	1	0
Pulmonary Cancer	low	1	0
Pulmonary Neoplasms	low	1	0
Renal Cancer	low	1	0
Renal Neoplasms	low	1	0
Right Middle Cerebral Artery Infarction	low	1	0
SARS Coronavirus 2 Infection	low	2	0
SARS-CoV-2 Infection	low	2	0
Sensitivity and Specificity	low	1	0
Sprue	low	1	0
Sprue, Celiac	low	1	0
Sprue, Nontropical	low	1	0
Squamous Cell Carcinoma	low	1	0
Stomach Cancer	low	1	0
Stomach Neoplasms	low	1	0
Streptozocin Diabetes	low	1	0
Streptozotocin Diabetes	low	1	0
Stroke, Middle Cerebral Artery	low	1	0
T Cell Leukemia Lymphoma, HTLV I Associated	low	1	0
T Cell Leukemia, Adult	low	1	0
T-Cell Leukemia-Lymphoma, Adult	low	1	0
T-Cell Leukemia-Lymphoma, HTLV-I-Associated	low	1	0
T-Cell Leukemia, Adult	low	1	0
T-Lymphotropic Virus Type III Infections, Human	low	1	0
Tactile Allodynia	low	1	0
Tetanus	low	1	0
Thermal Allodynia	low	1	0
Thrombosis	low	1	0
Thrombosis, Middle Cerebral Artery	low	1	0
Thrombotic Infarction, Middle Cerebral Artery	low	1	0
Thrombus	low	1	0
Todd Paralysis	low	1	0
Todd's Paralysis	low	1	0
Toxico-Infectious Botulism	low	1	0
Transformation, Neoplastic Cell	low	1	0
Triple Negative Breast Cancer	low	1	0
Triple Negative Breast Neoplasms	low	1	0
Triple-Negative Breast Cancer	low	1	0
Triple-Negative Breast Neoplasm	low	1	0
Tumorigenesis	low	1	0
Tumorigenic Transformation	low	1	0
Tumors	medium	7	3
Tumors, Breast	low	2	0
Wound Botulism	low	1	0
Zika Fever	low	1	0
Zika Virus Disease	low	1	0
Zika Virus Infection	low	1	0
ZikV Infection	low	1	0

Substance	Description	Relationhip Strength	Studies	Classes	Roles
colchicine	[no description available]	medium	2	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
paclitaxel	[no description available]	medium	2	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
4-tert-butyl-(3-(2-chloroethyl)ureido)benzene	[no description available]	medium	2
ceu 98	[no description available]	medium	2
vinblastine sulfate	[no description available]	medium	1
carmofur	[no description available]	medium	5	organohalogen compound; pyrimidines
disulfiram	[no description available]	medium	5	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
ebselen	[no description available]	medium	6	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
alkannin	[no description available]	medium	2	naphthoquinone
N-[(5-methyl-1,2-oxazol-3-yl)carbonyl]-L-alanyl-L-valyl-N-{(2S,3E)-5-(benzyloxy)-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-leucinamide	[no description available]	medium	2	benzyl ester; isoxazoles; pyrrolidin-2-ones; tripeptide	anticoronaviral agent; antiviral agent; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
np 031112	[no description available]	medium	5	benzenes; naphthalenes; thiadiazolidine	anti-inflammatory agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
ribavirin	[no description available]	medium	2	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
shikonin	[no description available]	medium	2	hydroxy-1,4-naphthoquinone
favipiravir	[no description available]	medium	1	hydroxypyrazine; organofluorine compound; primary carboxamide	anticoronaviral agent; antiviral drug; EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor
hirsutanone	[no description available]	medium	2	diarylheptanoid
4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione	[no description available]	medium	2	benzenes; thiadiazolidine	anti-inflammatory agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
sid 26681509	[no description available]	medium	1	carbohydrazide; L-tryptophan derivative; secondary carboxamide; tert-butyl ester; thioester	antiplasmodial drug; cathepsin L (EC 3.4.22.15) inhibitor
penciclovir	[no description available]	medium	1	2-aminopurines; propane-1,3-diols	antiviral drug
amodiaquine	[no description available]	medium	1	aminoquinoline; organochlorine compound; phenols; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; drug allergen; EC 2.1.1.8 (histamine N-methyltransferase) inhibitor; non-steroidal anti-inflammatory drug; prodrug
astemizole	[no description available]	medium	1	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
camostat	[no description available]	medium	2	benzoate ester; carboxylic ester; diester; guanidines; tertiary carboxamide	anti-inflammatory agent; anticoronaviral agent; antifibrinolytic drug; antihypertensive agent; antineoplastic agent; antiviral agent; serine protease inhibitor
chloroquine	[no description available]	medium	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorpromazine	[no description available]	medium	1	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
clomipramine	[no description available]	medium	1	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
emodin	[no description available]	medium	1	trihydroxyanthraquinone	antineoplastic agent; laxative; plant metabolite; tyrosine kinase inhibitor
fluphenazine	[no description available]	medium	1	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
fluspirilene	[no description available]	medium	1	diarylmethane
hydroxychloroquine	[no description available]	medium	2	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
hydroxyzine	[no description available]	medium	1	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
loperamide	[no description available]	medium	1	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
mefloquine hydrochloride	[no description available]	medium	1	organofluorine compound; piperidines; quinolines; secondary alcohol
niclosamide	[no description available]	medium	2	benzamides; C-nitro compound; monochlorobenzenes; salicylanilides; secondary carboxamide	anthelminthic drug; anticoronaviral agent; antiparasitic agent; apoptosis inducer; molluscicide; piscicide; STAT3 inhibitor
promethazine	[no description available]	medium	1	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
imatinib	[no description available]	medium	1	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
thiethylperazine	[no description available]	medium	1	N-methylpiperazine; phenothiazines	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
triflupromazine	[no description available]	medium	1	organofluorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; first generation antipsychotic
cycloheximide	[no description available]	medium	1	antibiotic fungicide; cyclic ketone; dicarboximide; piperidine antibiotic; piperidones; secondary alcohol	anticoronaviral agent; bacterial metabolite; ferroptosis inhibitor; neuroprotective agent; protein synthesis inhibitor
chlorphenoxamine	[no description available]	medium	1	diarylmethane	anticoronaviral agent
triparanol	[no description available]	medium	1	stilbenoid	anticoronaviral agent
emetine	[no description available]	medium	1	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor

1-methylpropyl-2-imidazolyl disulfide

Description

Cross-References

Synonyms (45)

Drug Classes (1)

Protein Targets (14)

Potency Measurements

Inhibition Measurements

Biological Processes (59)

Molecular Functions (35)

Ceullar Components (27)

Bioassays (89)

Research

Studies (61)

Study Types

Related Drugs (385)

Related Conditions (367)

Research Highlights

Safety/Toxicity (1)

Pharmacokinetics (1)

Bioavailability (1)

Dosage (1)